



2nd May 2025

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544250

The Secretary
National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza,
Bandra-Kurla Complex,
Bandra East, Mumbai - 400 051
Symbol: SANOFICONR

Sub.: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release / Media Release

Dear Sir/Madam,

We wish to inform you that the Board of Directors at its meeting held today i.e., Friday, 2nd May 2025, *inter-alia* considered and approved the Unaudited Financial Results for the quarter ended 31st March 2025. In this regard, please find enclosed a press release for your information and record.

Thanking You,

Yours faithfully
For Sanofi Consumer Healthcare India Limited

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: F7048

Sanofi Consumer Healthcare India Ltd. Q1 results PAT up 12.9%

Mumbai, 2nd May, 2025: Sanofi Consumer Healthcare India Ltd. announced its Q1 results with PAT at ₹500 million, which stands 12.9% above last quarter of Q4 2024. With an increase of ₹2.4 per share, landing the EPS at ₹21.7. The Company reported revenue from operations of ₹1726 million.

Commenting on the results, **Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited**, *“We continue to focus on strengthening our operations and continues to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.”*

The Q1 2025 also witnessed a successful launch of Allegra D, an addition to the existing portfolio of Allegra variants in India; a brand with over 25 years legacy in India.

Q1 2025 and Q1 2024 are not directly comparable, due to demerger and voluntary product recall of certain variants of key brands.

About Sanofi Consumer Healthcare India Ltd.

SCHIL has emerged as a distinct legal entity following its demerger from Sanofi India Limited. This demerger, executed under the Scheme of Arrangement, was sanctioned by the Mumbai bench of the National Company Law Tribunal and became effective on 1st June 2024. In alignment with Sanofi's global strategy, SCHIL is now operating independently, with a dedicated focus on the Consumer Healthcare sector.

With an agile business model and strong brands, SCHIL is one of the leading players in India's consumer healthcare market. Leveraging its global experience in consumer healthcare, Sanofi Consumer Healthcare India Limited (SCHIL) aims to enhance customer wellbeing through its portfolio of products which encompasses Allergy, Digestive Wellness, Pain Care, and Multivitamins and Herbal/Traditional Dietary Supplements. SCHIL's key brands include Allegra®, DePURA®, Avil®, and Combiflam®. They are dedicated to building a healthier future for their customers by empowering people to take control of their health, through self-care and by addressing their everyday health concerns.

Contacts SCHIL Media Relations; Nida Paloba | +91 9821017561 | nida.paloba@sanofi.com